secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRONWOOD PHARMACEUTICALS INC (IRWD)
CIK:        0001446847
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001104659-24-086992
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ironwood Q2 revenue down 12% to $94.4M; cuts FY 2024 guidance on Medicaid pricing
--------------------------------------------------------------------------------

- Total revenue $94.4M in Q2 2024, down 12% from $107.4M in Q2 2023; FY 2024 guidance revised lower due to pricing pressure.
- LINZESS prescription demand up 11% YoY but Medicaid utilization drove pricing headwinds; new-to-brand growth 15%.
- GAAP net loss of $0.9M (($0.01)/share) vs $1.06B loss in Q2 2023; adjusted EBITDA of $27.9M vs $(1.03B) last year.
- Plans to pursue apraglutide rolling NDA for short bowel syndrome; expects submission in Q1 2025. CNP-104 topline results on track for Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1446847/000110465924086992/0001104659-24-086992-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1446847/000110465924086992/tm2421104d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-086992

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer